Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.75 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxindole SCHEMBL3866757 | 0.89 | AHR (0.75) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL3802438 | 0.89 | AHR (0.81) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL19504 | 0.87 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL29358826 | 0.87 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL1144643 | 0.87 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL28460043 | 0.85 | AHR (0.88) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL5668060 | 0.85 | AHR (0.95) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL1236964 | 0.85 | AHR (0.95) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL8866524 | 0.85 | AHR (0.95) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL4720301 | 0.85 | AHR (0.95) | AHRPDK2NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3696276-A1 | NOVEL ANDROGEN RECEPTOR MUTATION | Novartis AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3327144-B1 | NOVEL ANDROGEN RECEPTOR MUTATION | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10011874-B2 | Androgen receptor mutation | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| EP-3327144-A1 | NOVEL ANDROGEN RECEPTOR MUTATION | Novartis AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160002727-A1 | NOVEL ANDROGEN RECEPTOR MUTATION | NOVARTIS AG (CH) | 2016-01-07 | — | — | US | disclosed |
| EP-2959013-A2 | NOVEL ANDROGEN RECEPTOR MUTATION | Novartis AG (CH) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130932-A9 | NOVEL ANDROGEN RECEPTOR MUTATION | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014130932-A2 | NOVEL ANDROGEN RECEPTOR MUTATION | NOVARTIS AG (CH) | 2014-08-28 | — | — | WO | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002727-A1 | NOVEL ANDROGEN RECEPTOR MUTATION | AR, BRCA1, SHBG | AHR 1297/4885PDK2 2788/4885NPC1 4023/4885 |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | AHR 233/4885PDK2 1510/4885NPC1 116/4885 |
| US-10011874-B2 | Androgen receptor mutation | AR, BRCA1, SHBG | AHR 854/4885PDK2 2874/4885NPC1 4154/4885 |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | AHR 579/4885PDK2 317/4885NPC1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.